ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-4800ometendo-4800Research ArticleСтатьиArticlesСтатины в лечении дислипидемии при сахарном диабете 2 типаStatiny v lechenii dislipidemii pri sakharnom diabete 2 tipaMel'nichenkoG A-GlinkinaI V-20051503200521№1 (2005)2126Copyright © Mel'nichenko G.A., Glinkina I.V., 20052005Mel'nichenko G.A., Glinkina I.V.Mel'nichenko G.A., Glinkina I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/4800ReferencesАронов Д.М. Плеотропные эффекты статинов. Русский медицинский журнал, т. 9, №13-14.Аронов Д.М. Плеотропные эффекты статинов. Русский медицинский журнал, т. 9, №13-14.Шевченко О.П., Шевченко А.П. Статины - ингибиторы ГМГ- КоА-редуктазы. «Реафарм», 2003.Шевченко О.П., Шевченко А.П. Статины - ингибиторы ГМГ- КоА-редуктазы. «Реафарм», 2003.American Diabetes Association. Management of dyslipidemia in adults with dia- betes (position statement). Diabetes Саге 2002, 25 (suppl.) S74- 77.American Diabetes Association. Management of dyslipidemia in adults with dia- betes (position statement). Diabetes Саге 2002, 25 (suppl.) S74- 77.American Diabetes Association. Evidence-based nutrition principles and recom- mendations for the treatment and prevention of diabetes and related complication (position statement). Diabetes Саге 2002, 25 (suppl.) S50- 60.American Diabetes Association. Evidence-based nutrition principles and recom- mendations for the treatment and prevention of diabetes and related complication (position statement). Diabetes Саге 2002, 25 (suppl.) S50- 60.American Diabetes Association. Diabetes mellitus and exercise (position state- ment). Diabetes Саге 2001, 24 (suppl.) S51-55.Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.American Diabetes Association. Diabetes mellitus and exercise (position state- ment). Diabetes Саге 2001, 24 (suppl.) S51-55.Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.Angulo P. Nonalcoholik fatty liver disease. N Engl 3 Med 2002, 346: 1221-1231.Angulo P. Nonalcoholik fatty liver disease. N Engl 3 Med 2002, 346: 1221-1231.Brown CDA, Windass А, Bleasby К, Lauffart В. Rosuvastatin is а high affinity sub- strate of hepatic organic anion transporter ОАТР-С. Atherosclerosis 2001, 2: 90.Brown CDA, Windass А, Bleasby К, Lauffart В. Rosuvastatin is а high affinity sub- strate of hepatic organic anion transporter ОАТР-С. Atherosclerosis 2001, 2: 90.Buckett L, Ballard Р, Davidson R et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus nonhepatic cells. Atherosclerosis 2002, 151: 41.Buckett L, Ballard Р, Davidson R et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus nonhepatic cells. Atherosclerosis 2002, 151: 41.Cressman MD, Hoogwerf BJ et al. HMG-CoA-reductase inhibitors. А new approach to the management of hypercholesterolemia Cleve Clin J Mes 1998, 55:93-110.Cressman MD, Hoogwerf BJ et al. HMG-CoA-reductase inhibitors. А new approach to the management of hypercholesterolemia Cleve Clin J Mes 1998, 55:93-110.Davidson МН. 11 Rosuvastatin: а highly efficacious statin for treatment of dyslip- idaemia. Expert Opin Investig Drugs 2002, (1):125-141.Davidson МН. 11 Rosuvastatin: а highly efficacious statin for treatment of dyslip- idaemia. Expert Opin Investig Drugs 2002, (1):125-141.Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduc- tion with pravastatin in diabetic and glucose-intolerant myocardial infarction sur- vivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) Trial. Circulation 1998, 98:2513-2519.Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduc- tion with pravastatin in diabetic and glucose-intolerant myocardial infarction sur- vivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) Trial. Circulation 1998, 98:2513-2519.Haffner SM, Alexander СМ, Cook TJ et al. Reduced coronary events in simvas- tatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Intern Med 1999, 159: 2661-2667.Haffner SM, Alexander СМ, Cook TJ et al. Reduced coronary events in simvas- tatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Intern Med 1999, 159: 2661-2667.Haffner SM, Lehto S, Ronemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and non-diabetic subjects ahd without prior myocar- dial infarction. New Engl J Med 1998, 339: 229-234.Haffner SM, Lehto S, Ronemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and non-diabetic subjects ahd without prior myocar- dial infarction. New Engl J Med 1998, 339: 229-234.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin 5963 people with diabetes: randomized placebo-controlled trial. Lancet 2003, 361: 2005- 2016.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin 5963 people with diabetes: randomized placebo-controlled trial. Lancet 2003, 361: 2005- 2016.Henry R. Preventing сardiovascular complications of type 2 diabetes: focus on lipid management. Clinical Diabetes 2001: 19(3).Henry R. Preventing сardiovascular complications of type 2 diabetes: focus on lipid management. Clinical Diabetes 2001: 19(3).Hsu I, Spinier SA, et al. Comparative evaluation of the safety and efficacy of НМС- СоА-reductase inhibitors monotherapy in the treatment of primary hypercholes- terolemia. Ann Pharmacol 1995, 29: 743-759.Hsu I, Spinier SA, et al. Comparative evaluation of the safety and efficacy of НМС- СоА-reductase inhibitors monotherapy in the treatment of primary hypercholes- terolemia. Ann Pharmacol 1995, 29: 743-759.Jones PH et al. Comparison of the efficacy and safety of rosuvastatin versus ator- vastatin,simvastatin and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003, 92: 152-160.Jones PH et al. Comparison of the efficacy and safety of rosuvastatin versus ator- vastatin,simvastatin and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003, 92: 152-160.Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for car- diovascular disease: the Framingam Study. Diabetes Care 1979, 2:120-126.Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for car- diovascular disease: the Framingam Study. Diabetes Care 1979, 2:120-126.Krolewski AS, Warram JH, Valsania P, Martin BC, Laffel LM, Christlieb AR. Evolving natural history of coronary heart disease in diabetes mellitus. Am J Med 1991, 90: 56S-61S.Krolewski AS, Warram JH, Valsania P, Martin BC, Laffel LM, Christlieb AR. Evolving natural history of coronary heart disease in diabetes mellitus. Am J Med 1991, 90: 56S-61S.Malmberg K, , Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, PiegasL, Calvin J, Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patienrs with unstuble angina and non-Q-wave myocardial infarction> results of OASIS Registry. Circulation 2000, 102:1014-1019.Malmberg K, , Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, PiegasL, Calvin J, Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patienrs with unstuble angina and non-Q-wave myocardial infarction> results of OASIS Registry. Circulation 2000, 102:1014-1019.Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J. Impact of diabetes on mortality after first myocardial infarction the FINNMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998, 21: 69-75.Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J. Impact of diabetes on mortality after first myocardial infarction the FINNMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998, 21: 69-75.National Diabetes Education Program. Control the ABCs of Diabetes, 2002National Diabetes Education Program. Control the ABCs of Diabetes, 2002Pyorala K, Pederson TR, Kjekshus J et al. Cholesterol lowering with simvastatin improves prognosis in diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20 614-620.Pyorala K, Pederson TR, Kjekshus J et al. Cholesterol lowering with simvastatin improves prognosis in diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20 614-620.Sprafka JM, Burke GL, Folsom AR, McGovern PG, Hahn LP. Trends in preva- lence of diabetes mellitus in patients with myocardial infarction and effect of dia- betes on survival the Minnesota Heart Study. Diabetes Care 1991, 14: 537-543.Sprafka JM, Burke GL, Folsom AR, McGovern PG, Hahn LP. Trends in preva- lence of diabetes mellitus in patients with myocardial infarction and effect of dia- betes on survival the Minnesota Heart Study. Diabetes Care 1991, 14: 537-543.Stein ЕА. Managing dyslipidemia in the high-risk patient. Am 3 Cardiol 2002, 89 (suppl):50с-57с.Stein ЕА. Managing dyslipidemia in the high-risk patient. Am 3 Cardiol 2002, 89 (suppl):50с-57с.The Long-term Intervention of Pravastatin on Ischaemic Disease (LIPID) Study Group. Prevenion of cardiovascular events and death with pravastatin in patient with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339: 1349-1357.The Long-term Intervention of Pravastatin on Ischaemic Disease (LIPID) Study Group. Prevenion of cardiovascular events and death with pravastatin in patient with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339: 1349-1357.Tuomilehto J. Interrupting the atherosclerotic process in diabetes: when and how should we treat? Advanced studies in medicine 2002, 2 (22): 800- 807.Tuomilehto J. Interrupting the atherosclerotic process in diabetes: when and how should we treat? Advanced studies in medicine 2002, 2 (22): 800- 807.UK Prospective Diabetes Study (UKPDS) Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. Diabetes Care 2002, 25 (suppl.): S74-77.UK Prospective Diabetes Study (UKPDS) Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. Diabetes Care 2002, 25 (suppl.): S74-77.Jones P, Davidson M, Stein E, Bays H, McKenney J, Miller E, Cain V, Blasetto J. Comparison of the efficacy and asfety of rosuvastatin versus atorvastatin, sim- vastatin and pravastatin across doses (STELLAR Trial). Am .J. Cardiol. 2003; 93:152-160.Jones P, Davidson M, Stein E, Bays H, McKenney J, Miller E, Cain V, Blasetto J. Comparison of the efficacy and asfety of rosuvastatin versus atorvastatin, sim- vastatin and pravastatin across doses (STELLAR Trial). Am .J. Cardiol. 2003; 93:152-160.Оlsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolaemia. Am. Heart J., 2002;144:1044-51.Оlsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolaemia. Am. Heart J., 2002;144:1044-51.
The authors declare that there are no conflicts of interest present.